Workflow
Loop Industries(LOOP) - 2024 Q4 - Annual Report

Revenue Performance - Revenues for the three-month period ended February 29, 2024, increased by 33to33 to 45, compared to 12forthesameperiodin2023,drivenbyinitialdeliveriesofLoopPETresin[221].ForthefiscalyearendedFebruary29,2024,revenuesdecreasedby12 for the same period in 2023, driven by initial deliveries of Loop™ PET resin [221]. - For the fiscal year ended February 29, 2024, revenues decreased by 20 to 153,comparedto153, compared to 173 for the same period in 2023, attributed to initial deliveries of Loop™ PET resin [227]. - Revenue for the year ended February 29, 2024, was 153,000,adecreaseof11.6153,000, a decrease of 11.6% compared to 173,000 for the year ended February 28, 2023 [287]. Net Loss and Financial Performance - The net loss for the three-month period ended February 29, 2024, increased by 10,514to10,514 to 5,091, compared to a net income of 5,423forthesameperiodin2023,largelyduetoapriorgainonlanddispositionof5,423 for the same period in 2023, largely due to a prior gain on land disposition of 9,980 [224]. - The net loss for the year ended February 29, 2024, decreased by 214to214 to 21,087, compared to 21,301forthesameperiodin2023[230].TheCompanyincurredanetlossof21,301 for the same period in 2023 [230]. - The Company incurred a net loss of 21.1 million for the year ended February 29, 2024, with net cash flows used from operating activities amounting to 18.0million[276].Comprehensivelossdecreasedto18.0 million [276]. - Comprehensive loss decreased to 21,016,000 from 22,346,000,reflectinga5.922,346,000, reflecting a 5.9% improvement [287]. - Basic and diluted net loss per share was 0.44, compared to 0.45inthepreviousyear,indicatingaminorimprovement[287].ResearchandDevelopmentExpensesResearchanddevelopmentexpensesforthethreemonthperiodendedFebruary29,2024,roseby0.45 in the previous year, indicating a minor improvement [287]. Research and Development Expenses - Research and development expenses for the three-month period ended February 29, 2024, rose by 805 to 3,018,primarilyduetoan3,018, primarily due to an 866 increase in plant and laboratory operating expenses, including an inventory write-down of 817[222].TotalresearchanddevelopmentexpensesforthefiscalyearendedFebruary29,2024,were817 [222]. - Total research and development expenses for the fiscal year ended February 29, 2024, were 11,379, a decrease of 5,967fromthepreviousyear[226].Researchanddevelopmentexpensesdecreasedby5,967 from the previous year [226]. - Research and development expenses decreased by 5,967 to 11,379fortheyearendedFebruary29,2024,comparedto11,379 for the year ended February 29, 2024, compared to 17,346 for the same period in 2023 [228]. - Research and development expenses primarily relate to process development, customer trials, and testing of pre-production samples, and are presented net of related tax credits and government grants [313]. Cash Flow and Liquidity - Cash and cash equivalents on hand were 6,958asofFebruary29,2024,withanundrawnseniorloanfacilityof6,958 as of February 29, 2024, with an undrawn senior loan facility of 2,579 [230]. - Net cash used in operating activities was 18,034fortheyearendedFebruary29,2024,comparedto18,034 for the year ended February 29, 2024, compared to 34,892 for the year ended February 28, 2023 [244]. - The company has incurred net losses and negative cash flow from operating and investing activities since its inception, with no material revenues from customers [302]. - Management estimates that current available liquidity and forecasted net cash flows will not be sufficient to meet the company's obligations over the next twelve months [303]. - As of February 29, 2024, the Company's available liquidity was 9.5million,consistingofcashandcashequivalentsof9.5 million, consisting of cash and cash equivalents of 6.9 million and an undrawn senior loan facility of 2.6million[276].GeneralandAdministrativeExpensesGeneralandadministrativeexpensesforthethreemonthperiodendedFebruary29,2024,increasedby2.6 million [276]. General and Administrative Expenses - General and administrative expenses for the three-month period ended February 29, 2024, increased by 22 to 2,221,primarilyduetoanincreaseinstockbasedcompensation[223].Generalandadministrativeexpensesdecreasedby2,221, primarily due to an increase in stock-based compensation [223]. - General and administrative expenses decreased by 10,441 to 9,988fortheyearendedFebruary29,2024,comparedto9,988 for the year ended February 29, 2024, compared to 20,429 for the same period in 2023 [229]. - General and administrative expenses for the year ended February 29, 2024 were 9,988,000,down51.19,988,000, down 51.1% from 20,429,000 in the prior year [390]. Debt and Financing - The company is pursuing financing for its planned manufacturing facilities, which is critical for moving to the next stage of strategic development [218]. - The Company has a long-term debt obligation of up to 3,390relatedtotheexpansionoftheTerrebonneFacility,withrepaymentsstructuredover72monthlyinstallments[234].Thecompanyisseekingtofinalizenegotiationsforpreviouslyannouncedfinancinginitiativesonacceptableterms[232].Totalrepaymentsdueonthecompanysindebtednessoverthenextfiveyearsamountto3,390 related to the expansion of the Terrebonne Facility, with repayments structured over 72 monthly installments [234]. - The company is seeking to finalize negotiations for previously announced financing initiatives on acceptable terms [232]. - Total repayments due on the company's indebtedness over the next five years amount to 3,511 [371]. - Interest expense on the Investissement Québec loan for the year ended February 29, 2024, was 84,comparedto84, compared to 86 in 2023 [366]. Inventory and Assets - The company reported total inventories of 102,000asofFebruary29,2024,adecreasefrom102,000 as of February 29, 2024, a decrease from 727,000 in the previous year, with an allowance for inventory write-down of 817,000recorded[343].Thetotalcurrentassetsdecreasedfrom817,000 recorded [343]. - The total current assets decreased from 36.4 million as of February 28, 2023, to 8.0millionasofFebruary29,2024[282].Thetotalstockholdersequitydecreasedfrom8.0 million as of February 29, 2024 [282]. - The total stockholders' equity decreased from 33.7 million as of February 28, 2023, to 14.1millionasofFebruary29,2024[284].StrategicDevelopmentsAstrategicpartnershipwithEsterwasannouncedtobuildanInfiniteLoopmanufacturingfacilityinIndia,expectedtocommencecommercialoperationsinearly2027[212].TheplannedfacilityinUlsan,SouthKorea,isexpectedtosupplyupto70,000metrictonsperyearofLoopPETresin,withconstructiontimingcurrentlyunderreview[215].Thecompanyintendstocontinueexecutingitscorporatestrategy,focusingoncommercializationofInfiniteLoopTechnologyandsecuringfinancingforoperationsandprojects[248].StockBasedCompensationStockbasedcompensationexpenseswere14.1 million as of February 29, 2024 [284]. Strategic Developments - A strategic partnership with Ester was announced to build an Infinite Loop™ manufacturing facility in India, expected to commence commercial operations in early 2027 [212]. - The planned facility in Ulsan, South Korea, is expected to supply up to 70,000 metric tons per year of Loop™ PET resin, with construction timing currently under review [215]. - The company intends to continue executing its corporate strategy, focusing on commercialization of Infinite Loop™ Technology and securing financing for operations and projects [248]. Stock-Based Compensation - Stock-based compensation expenses were 1,422,000, significantly lower than 10,086,000inthepreviousyear[294].StockbasedcompensationattributabletostockoptionsfortheyearendedFebruary29,2024amountedto10,086,000 in the previous year [294]. - Stock-based compensation attributable to stock options for the year ended February 29, 2024 amounted to 644,000, compared to 1,316,000in2023[393].StockbasedcompensationattributabletoRSUsfortheyearendedFebruary29,2024,amountedto1,316,000 in 2023 [393]. - Stock-based compensation attributable to RSUs for the year ended February 29, 2024, amounted to 778, a significant decrease from $8,770 in 2023 [396]. - The total number of outstanding restricted stock units (RSUs) at the end of 2024 was 4,368,897, compared to 3,888,618 at the end of 2023, reflecting an increase of approximately 12.3% [395].